人造
发表于 2025-3-26 21:30:37
Survival Signaling,ole in controlling cell growth, proliferationand survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in human cancercells has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents.Although often non-selective for the intended
连词
发表于 2025-3-27 01:58:10
Progress in the Development of Agents to Control the Cell Cycle,rts have focused on inhibitors of the cyclin-dependentkinases, the Aurora kinases, and Polo-like kinases. Agents for each kinase are now advancing in humanclinical trials. In this review we will summarize the work in this area with special emphasis onthe structural biology and structure–activity rel
Annotate
发表于 2025-3-27 05:35:32
HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinicical background of HDACs and their link to cancer andcancer treatment. The body of the work consists of a categorized and chronological medicinal chemistryoverview. This part describes key medicinal chemistry contributions ranging from the very early HDAC inhibitorsto compounds currently in the clin
使服水土
发表于 2025-3-27 12:34:46
Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancerof the molecular mechanisms underlyingthe angiogenesis process have led to the discovery of a variety of pharmaceutical agents withantiangiogenic activity. The potential application of these angiogenesis inhibitors is currentlyunder intense clinical investigation. Decades of investigation suggest t
发出眩目光芒
发表于 2025-3-27 14:24:15
http://reply.papertrans.cn/23/2211/221038/221038_35.png
META
发表于 2025-3-27 18:44:46
Bcr-Abl Kinase Inhibitors,-phenyl aminopyrimidine Bcr-Abl inhibitor developedby Novartis and marketed under the tradename of Gleevec (Glivec), is highly effective in treating CML patientswith early stage disease. However, patients with advanced disease often become resistant to imatinib. Thepredominant form of this resistanc
DUCE
发表于 2025-3-27 23:18:54
http://reply.papertrans.cn/23/2211/221038/221038_37.png
Coterminous
发表于 2025-3-28 04:50:42
Neuroprotection for Photoreceptorsased potency and efficacy, improved tissueselectivity, and without any agonistic activity will be described. New pre-clinical and clinical data ondevelopment candidates will be reported. Advanced breast and prostate cancer is effectively managed byestrogen and androgen ablation, respectively. Howeve
Eosinophils
发表于 2025-3-28 09:14:00
http://reply.papertrans.cn/23/2211/221038/221038_39.png
degradation
发表于 2025-3-28 11:28:11
https://doi.org/10.1007/978-981-99-7269-2logy of the VEGF family of ligands and receptors and of VEGFR-2 in particular.The attempts to develop effective VEGFR-2 antagonists, including small molecules, antibodies and others,for therapeutic purposes are discussed comprehensively with special emphasis on tumor angiogenesis.